3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
2
Classical hematology
1
Conditions
Anemia
43
Anemia, Refractory, with Excess of Blasts
40
Leukemia, Myeloid, Acute
38
Myelodysplastic Syndromes
36
Leukemia
34
Neoplasms
29
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Multiple Myeloma
25
Thrombocytopenia
23
Leukemia, Lymphocytic, Chronic, B-Cell
21
Primary Myelofibrosis
20
Lymphoma
20
Lymphoma, Non-Hodgkin
19
Leukemia, Myelomonocytic, Chronic
18
Venous Thromboembolism
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Hodgkin Disease
16
Myeloproliferative Disorders
15
Lymphoma, Mantle-Cell
14
Anemia, Aplastic
14
Anemia, Refractory
13
Lymphoma, Follicular
12
Hematologic Neoplasms
12
Lymphoma, Large B-Cell, Diffuse
11
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Myelodysplastic-Myeloproliferative Diseases
9
Lymphoma, Large-Cell, Immunoblastic
9
Leukemia, Myeloid, Chronic-Phase
9
Burkitt Lymphoma
9
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts